CSIMarket
 
Matinas Biopharma Holdings Inc   (MTNB)
 

News




Matinas BioPharma Pioneers Revolutionary Oral Therapy for Invasive Fungal Infections

MAT2203: Promising Breakthrough in Treating Invasive Fusarium Infections

Matinas BioPharma*s Promising Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma*s MAT2203 Granted Pathway for Single Phase 3 Trial Supporting Potential Breakthrough Treatment for Invasive Aspergillosis

Revolutionizing Inflammatory Disease Treatment: Matinas BioPharma*s Oral LNC-Delivered Small Oligonucleotides Show Promise in Groundbreaking Study

Matinas BioPharma Nearing FDA Alignment for MAT2203 Phase 3 Registration Trial: A Promising Development

Matinas BioPharma Faces NYSE American Continued Listing Deficiency, Takes Swift Action to Address Compliance

: { message: The server had an error while processing your request. Sorry about that! You can retry your request, or contact us through our help center at help.openai.com if the error persists. (Please

Matinas Biopharma Holdings Inc Reports $1.096 Million in Revenue, Despite Challenging Industry Conditions

The Major Pharmaceutical Preparations company announced Revenue of $1.063 millions, in the fiscal interval ending December 31 2022

A Blowout performance, by the Matinas Biopharma Holdings Inc all along the second quarter of 2022

The revenue are the comparable like a year before at the Matinas Biopharma Holdings Inc in the most recent fiscal period

A deficit of $-0.03 per Share at the MTNB in financial span ending September 30 2021









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com